Ubs Group Ag Erasca, Inc. Transaction History

Ubs Group Ag

$527 Billion
Q4 2024

A detailed history of Ubs Group Ag transactions in Erasca, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 193,168 shares of ERAS stock, worth $303,273. This represents 0.0% of its overall portfolio holdings.

Number of Shares

193,168

Previous 230,622 16.24%

Holding current value

$303,273

Previous $629,000 23.05%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	$2.44 - $3.23 $91,387 - $120,976	-37,454 Reduced 16.24%	193,168 $484,000
Q3 2024 Nov 14, 2024	BUY	$2.17 - $3.28 $402,526 - $608,426	185,496 Added 411.06%	230,622 $629,000
Q2 2024 Aug 13, 2024	SELL	$1.79 - $2.63 $61,567 - $90,458	-34,395 Reduced 43.25%	45,126 $106,000
Q1 2024 May 13, 2024	SELL	$1.67 - $2.55 $53,981 - $82,426	-32,324 Reduced 28.9%	79,521 $163,000
Q4 2023 Feb 09, 2024	BUY	$1.67 - $2.49 $95,445 - $142,310	57,153 Added 104.5%	111,845 $238,000
Q3 2023 Nov 09, 2023	SELL	$1.97 - $2.91 $248 - $366	-126 Reduced 0.23%	54,692 $107,000
Q2 2023 Aug 11, 2023	BUY	$2.57 - $3.3 $60,531 - $77,724	23,553 Added 75.33%	54,818 $151,000
Q1 2023 May 12, 2023	SELL	$2.74 - $4.44 $454,987 - $737,279	-166,054 Reduced 84.16%	31,265 $94,000
Q4 2022 Feb 08, 2023	BUY	$3.89 - $8.57 $756,387 - $1.67 Million	194,444 Added 6763.27%	197,319 $850,000
Q3 2022 Nov 10, 2022	BUY	$5.82 - $10.68 $16,732 - $30,705	2,875 New	2,875 $23,000
Q1 2022 May 16, 2022	SELL	$8.6 - $15.48 $64,749 - $116,548	-7,529 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$12.51 - $22.75 $85,118 - $154,791	6,804 Added 938.48%	7,529 $118,000
Q3 2021 Nov 15, 2021	BUY	$17.43 - $24.34 $12,636 - $17,646	725 New	725 $15,000

Others Institutions Holding ERAS

# of Institutions

153

Shares Held

221M

Call Options Held

10.1K

Put Options Held

79.3K

View Full List

About Erasca, Inc.

Ticker ERAS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 122,147,000
Market Cap $192M
Description
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...

More about ERAS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account